Status:

UNKNOWN

Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non-small Cell Lung Cancer (NSCLC)

Lead Sponsor:

Xijing Hospital

Collaborating Sponsors:

Yantai Medgenn Ltd.

Conditions:

Lung Neoplasms

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

To study the impact of endostar combined with docetaxel and cisplatin on the angiogenesis of non-small cell lung cancer, patients will be randomly assigned to the group one (endostar combined with doc...

Detailed Description

To study the impact of endostar combined with docetaxel and cisplatin on the angiogenesis of non-small cell lung cancer,patients will be randomly assigned to the experimental group(endostar combined w...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of advanced or metastatic NSCLC (confirmed histologically, with a tumor that was measurable by clinical and/or radiologic examination.
  • Have an Eastern Cooperative Oncology Group performance status 0 to 2.
  • Adequate renal, cardiac, hepatic, and hematologic function as indicated by the following parameters: absolute neutrophil count 2 x the ninth power of ten/L, thrombocytes 100 x the ninth power of ten/L, hemoglobin 10 g/dL, total bilirubin 1.25x the upper limit of normal range (ULN), ALT and AST 1.5x ULN, alkaline phosphatase 5x ULN, creatinine 1.15x ULN.

Exclusion

  • Known brain metastases or secondary neoplasia.
  • Myocardial insufficiency or myocardial infarction within the preceding 6 months.
  • Severe renal or hepatic insufficiency.
  • Pre-existing motor or sensor neurotoxicity WHO grade 2.
  • Severe psychologic disease.
  • Active infection, or other condition that could compromise protocol compliance.
  • Simultaneous administration of other antineoplastic medications.
  • Clinically significant hemoptysis.
  • Pregnancy and/or lactation.

Key Trial Info

Start Date :

April 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2009

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT00657423

Start Date

April 1 2008

End Date

April 1 2009

Last Update

September 17 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Dept. Resp. Diseases, Xijing Hospital

Xi'an, Shaanxi, China, 710032